Revenue (Quarterly) Chart

Historical Revenue (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 9.512M
March 31, 2026 8.799M
December 31, 2025 10.47M
September 30, 2025 8.095M
June 30, 2025 6.964M
March 31, 2025 6.50M
December 31, 2024 7.895M
September 30, 2024 6.997M
June 30, 2024 6.131M
March 31, 2024 6.262M
December 31, 2023 7.337M
September 30, 2023 6.347M
June 30, 2023 6.02M
March 31, 2023 5.482M
December 31, 2022 6.157M
September 30, 2022 4.776M
June 30, 2022 4.246M
March 31, 2022 3.751M
December 31, 2021 4.081M
September 30, 2021 0.0225M
June 30, 2021 0.0157M
March 31, 2021 0.0141M
December 31, 2020 0.00
September 30, 2020 0.00
June 30, 2020 0.00
Date Value
March 31, 2020 0.00
December 31, 2019 0.00
September 30, 2019 0.00
June 30, 2019 0.00
March 31, 2019 0.00
December 31, 2018 0.00
September 30, 2018 0.00
June 30, 2018 0.00
March 31, 2018 0.00
December 31, 2017
September 30, 2017 0.00
June 30, 2017 0.00
March 31, 2017 0.00
December 31, 2016 0.00
September 30, 2016 0.00
June 30, 2016 0.00
March 31, 2016 0.00
February 29, 2016
November 30, 2015
August 31, 2015
May 31, 2015
February 28, 2015 0.00
November 30, 2014 0.00
August 31, 2014 0.00
May 31, 2014 0.00

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
Biomerica, Inc. 0.875M
Univec, Inc. 0.021M
Lantheus Holdings, Inc. 388.18M
IDEXX Laboratories, Inc. 1.217B
Neogen Corp. 225.30M